---
title: 'Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A
  inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients
  with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the
  combination''s pharmacokinetics, safety, andÂ efficacy'
date: '2023-11-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37920921/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231103180959&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Expression of CYP3A5 protein is a basal and acquired resistance mechanism
  of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A
  and CYP2C8 substrate paclitaxel through metabolic degradation. Inhibition of CYP3A
  isozymes restores the cells sensitivity to paclitaxel. The combination of gemcitabine
  and nab-paclitaxel is an established regimen for the treatment of metastasized or
  locally advanced inoperable pancreatic cancer. Cobicistat is a CYP3A inhibitor developed
  ...
disable_comments: true
---
Expression of CYP3A5 protein is a basal and acquired resistance mechanism of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A and CYP2C8 substrate paclitaxel through metabolic degradation. Inhibition of CYP3A isozymes restores the cells sensitivity to paclitaxel. The combination of gemcitabine and nab-paclitaxel is an established regimen for the treatment of metastasized or locally advanced inoperable pancreatic cancer. Cobicistat is a CYP3A inhibitor developed ...